Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLK-302 Phase 2 for Presbyopia
NCT05124275Phase 2Completed
- Sponsor
- Glaukos Corporation
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of GLK-302 in presbyopia, sponsored by Glaukos Corporation. Started Jan 2022; status: completed.
02
Drugs
GLK-302
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05124275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124275.